JPH08502044A - ヒトウイルス感染の治療 - Google Patents

ヒトウイルス感染の治療

Info

Publication number: JPH08502044A
Authority: JP; Japan
Prior art keywords: hiv; cells; hydrogen; ltr; substituted
Prior art date: 1992-08-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP6506587A

Other languages

English (en)

Japanese (ja)

Inventor

パーディー，アーサー・ビー

リー，ジア−キヤン

クラムパツカー，クライド

ツアン，リン

Original Assignee

デイナ・フアーバー・キヤンサー・インステイテユート

ベス・イスラエル・ホスピタル

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-21

Filing date

1993-08-23

Publication date

1996-03-05

1993-08-23 Application filed by デイナ・フアーバー・キヤンサー・インステイテユート, ベス・イスラエル・ホスピタル filed Critical デイナ・フアーバー・キヤンサー・インステイテユート

1996-03-05 Publication of JPH08502044A publication Critical patent/JPH08502044A/ja

Status Pending legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title description 14
208000036142 Viral infection Diseases 0.000 title description 2
230000009385 viral infection Effects 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 57
241000700605 Viruses Species 0.000 claims abstract description 23
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
239000001257 hydrogen Substances 0.000 claims abstract description 18
206010061598 Immunodeficiency Diseases 0.000 claims abstract description 15
208000029462 Immunodeficiency disease Diseases 0.000 claims abstract description 15
125000000217 alkyl group Chemical group 0.000 claims abstract description 15
230000007813 immunodeficiency Effects 0.000 claims abstract description 15
125000003342 alkenyl group Chemical group 0.000 claims abstract description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
150000002431 hydrogen Chemical class 0.000 claims abstract description 8
125000001424 substituent group Chemical group 0.000 claims abstract description 8
230000001939 inductive effect Effects 0.000 claims abstract 3
210000004027 cell Anatomy 0.000 claims description 92
241000725303 Human immunodeficiency virus Species 0.000 claims description 47
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 43
229960000303 topotecan Drugs 0.000 claims description 43
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 39
230000014509 gene expression Effects 0.000 claims description 35
238000000034 method Methods 0.000 claims description 30
108090000623 proteins and genes Proteins 0.000 claims description 15
229960002555 zidovudine Drugs 0.000 claims description 14
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 14
208000030507 AIDS Diseases 0.000 claims description 11
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 10
241000282412 Homo Species 0.000 claims description 9
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 7
WREGKURFCTUGRC-UHFFFAOYSA-N 4-Amino-1-[5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1OC(CO)CC1 WREGKURFCTUGRC-UHFFFAOYSA-N 0.000 claims description 2
210000005260 human cell Anatomy 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
230000000840 anti-viral effect Effects 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
239000000203 mixture Substances 0.000 description 23
108060008682 Tumor Necrosis Factor Proteins 0.000 description 21
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 21
230000000694 effects Effects 0.000 description 20
239000003814 drug Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 13
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
208000031886 HIV Infections Diseases 0.000 description 10
125000004432 carbon atom Chemical group C* 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
239000002609 medium Substances 0.000 description 10
230000010076 replication Effects 0.000 description 10
230000003833 cell viability Effects 0.000 description 9
102100034349 Integrase Human genes 0.000 description 8
108010005774 beta-Galactosidase Proteins 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
239000000523 sample Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
238000009825 accumulation Methods 0.000 description 6
230000004913 activation Effects 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
102000005936 beta-Galactosidase Human genes 0.000 description 6
125000004122 cyclic group Chemical group 0.000 description 6
238000009472 formulation Methods 0.000 description 6
125000004404 heteroalkyl group Chemical group 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
208000037357 HIV infectious disease Diseases 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
239000000427 antigen Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
208000037581 Persistent Infection Diseases 0.000 description 4
230000002411 adverse Effects 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000002502 liposome Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
229930182816 L-glutamine Natural products 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
125000002015 acyclic group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
108091092328 cellular RNA Proteins 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000000465 moulding Methods 0.000 description 3
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
LEAKQIXYSHIHCW-UHFFFAOYSA-N 7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine Chemical compound N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CN1 LEAKQIXYSHIHCW-UHFFFAOYSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
230000006819 RNA synthesis Effects 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Inorganic materials [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
229940043274 prophylactic drug Drugs 0.000 description 2
238000003345 scintillation counting Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001123946 Gaga Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700010908 HIV-1 proteins Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
241000726306 Irus Species 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
241001313288 Labia Species 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
241001024304 Mino Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000003973 alkyl amines Chemical group 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
-1 bacteriostats Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000010293 colony formation assay Methods 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229960005102 foscarnet Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000009432 framing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
210000001985 kidney epithelial cell Anatomy 0.000 description 1
238000003367 kinetic assay Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
229940051866 mouthwash Drugs 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP6506587A 1992-08-21 1993-08-23 ヒトウイルス感染の治療 Pending JPH08502044A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US93346092A	1992-08-21	1992-08-21
US07/933,460		1992-08-21
US632093A	1993-01-19	1993-01-19
US08/006,320		1993-01-19
PCT/US1993/007934 WO1994004160A1 (fr)	1992-08-21	1993-08-23	Traitement d'infections virales chez l'homme

Publications (1)

Publication Number	Publication Date
JPH08502044A true JPH08502044A (ja)	1996-03-05

Family

ID=26675474

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6506587A Pending JPH08502044A (ja)	1992-08-21	1993-08-23	ヒトウイルス感染の治療

Country Status (4)

Country	Link
EP (1)	EP0655919A4 (fr)
JP (1)	JPH08502044A (fr)
CA (1)	CA2142831A1 (fr)
WO (1)	WO1994004160A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5491237A (en)	1994-05-03	1996-02-13	Glaxo Wellcome Inc.	Intermediates in pharmaceutical camptothecin preparation
WO1997032587A1 (fr) *	1996-03-04	1997-09-12	Dana-Farber Cancer Institute	Methodes de traitement d'infections virales
US6395541B1 (en)	1996-05-23	2002-05-28	The Rockefeller University	Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6559309B2 (en)	1996-11-01	2003-05-06	Osi Pharmaceuticals, Inc.	Preparation of a camptothecin derivative by intramolecular cyclisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3682874D1 (de) *	1985-10-21	1992-01-23	Daiichi Seiyaku Co	Pyranoindolizinderivate und verfahren zu ihrer herstellung.
US5004758A (en) *	1987-12-01	1991-04-02	Smithkline Beecham Corporation	Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5422344A (en) *	1990-05-08	1995-06-06	The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Method of treating retroviral infections in mammals

1993
- 1993-08-23 CA CA002142831A patent/CA2142831A1/fr not_active Abandoned
- 1993-08-23 EP EP93920283A patent/EP0655919A4/fr not_active Withdrawn
- 1993-08-23 JP JP6506587A patent/JPH08502044A/ja active Pending
- 1993-08-23 WO PCT/US1993/007934 patent/WO1994004160A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO1994004160A1 (fr)	1994-03-03
EP0655919A4 (fr)	1995-10-18
EP0655919A1 (fr)	1995-06-07
CA2142831A1 (fr)	1994-03-03

Publication	Publication Date	Title
CN102791129B (zh)	2015-09-30	抗病毒治疗
Finnegan et al.	1996	IL-10 cooperates with TNF-α to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage
US5736527A (en)	1998-04-07	Method of treating HIV in humans by administration of ddI and hydroxycarbamide
Lazdins et al.	1991	In vitro effect of transforming growth factor-beta on progression of HIV-1 infection in primary mononuclear phagocytes
WO1994004145A9 (fr)	1994-06-09	Traitement d'infections virales chez l'homme
WO1994004145A1 (fr)	1994-03-03	Traitement d'infections virales chez l'homme
JP2001500471A (ja)	2001-01-16	プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法
CZ182492A3 (en)	1993-12-15	Pharmaceutical preparation for treating t-cellular leukemia (lymphoma of adults)
WO1991016904A1 (fr)	1991-11-14	Procede utile pour traiter des infections retrovirales chez des mammiferes
US5641773A (en)	1997-06-24	Methods for treating viral infections
EP0809504B1 (fr)	2002-05-15	Antiviral triazacyclododecane
JPH08502044A (ja)	1996-03-05	ヒトウイルス感染の治療
US20040116411A1 (en)	2004-06-17	Combination HIV therapy including camptothecin
US5519028A (en)	1996-05-21	Antiviral preparations
JP2004538334A (ja)	2004-12-24	Ｈｉｖ感染の治療に使用される薬剤とその成分と使用法
WO1996011005A2 (fr)	1996-04-18	Utilisation de camptothecine ou de derives de camptothecine dans la fabrication d'un medicament destine au traitement de maladies virales
WO1997037661A1 (fr)	1997-10-16	Medicament de prevention et de traitement des infections virales
WO1994004139A1 (fr)	1994-03-03	Traitement d'infections virales chez l'homme
CN1302779C (zh)	2007-03-07	含有阿巴卡韦和阿洛夫定的药物制剂及其用途
US11247996B2 (en)	2022-02-15	Small molecule inhibitors for transcription factors
WO1994004139A9 (fr)	1994-04-28	Traitement d'infections virales chez l'homme
CN116003258B (zh)	2024-09-24	12-o-辛酰基-佛波醇酯类衍生物及制备方法和应用
JPH07508998A (ja)	1995-10-05	抗ウイルス剤の組み合わせ
HU208254B (en)	1993-09-28	Hiv inhibition by applying synergetic combinations of nucleoside derivatives
WO1997032587A1 (fr)	1997-09-12	Methodes de traitement d'infections virales